Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,653 questions in 194 reviews · Gynaecology and Fertility
current versionsNo studies 531 · 20%Ungraded 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dopamine agonist plus co‐intervention vs co‐intervention Miscarriage rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 0.65 [0.3, 1.42] | 3 studies · 548 participants | Low |
Dopamine agonist plus co‐intervention vs co‐intervention Any other adverse events · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 3.03 [0.12, 75.28] | 2 studies · 366 participants | Very low |
Dopamine agonist vs other active intervention Incidence of moderate or severe OHSS · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 0.21 [0.12, 0.38] | 3 studies · 296 participants | Very low |
Dopamine agonist vs other active intervention Live birth rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 1.08 [0.73, 1.59] | 2 studies · 430 participants | Low |
Dopamine agonist vs other active intervention Clinical pregnancy rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 1.04 [0.81, 1.33] | 7 studies · 1060 participants | Moderate |
Dopamine agonist vs other active intervention Multiple pregnancy rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 0.87 [0.47, 1.59] | 3 studies · 400 participants | Low |
Dopamine agonist vs other active intervention Miscarriage rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 0.66 [0.35, 1.25] | 4 studies · 630 participants | Low |
Dopamine agonist vs other active intervention Any other adverse events · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | no estimate extracted | 1 study · 170 participants | Ungraded |
Dopamine agonist vs placebo/no intervention Live birth rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 0.96 [0.6, 1.55] | 3 studies · 362 participants | Low |
Dopamine agonist vs placebo/no intervention Clinical pregnancy rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 0.92 [0.63, 1.37] | 5 studies · 530 participants | Low |
Dopamine agonist vs placebo/no intervention Multiple pregnancy rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 0.32 [0.01, 8.26] | 1 study · 40 participants | Very low |
Dopamine agonist vs placebo/no intervention Miscarriage rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 0.66 [0.19, 2.28] | 2 studies · 168 participants | Low |
Dopamine agonist vs placebo/no intervention Any other adverse events · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 4.54 [1.49, 13.84] | 2 studies · 264 participants | Very low |
Dopamine agonist plus co‐intervention vs co‐intervention Incidence of moderate or severe OHSS · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 0.48 [0.28, 0.84] | 4 studies · 748 participants | Low |
Dopamine agonist plus co‐intervention vs co‐intervention Live birth rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 1.21 [0.81, 1.8] | 2 studies · 400 participants | Low |
Dopamine agonist plus co‐intervention vs co‐intervention Clinical pregnancy rate · women of reproductive age undergoing any ART therapy Dopamine agonists for preventing ovarian hyperstimulation syndrome (2021) · Cochrane | OR 1.11 [0.83, 1.49] | 4 studies · 748 participants | Low |
Endometrial injury vs control Live birth per woman randomised (studies at low risk of selection bias and other bias) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | OR 1.12 [0.98, 1.28] | 8 studies · 4402 participants | Moderate |
Higher vs lower degree of injury Live birth per woman randomised: sensitivity analysis (including all studies) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | OR 1.28 [0.31, 5.37] | 1 study · 129 participants | Very low |
Higher vs lower degree of injury Miscarriage per woman randomised: sensitivity analysis (including all studies) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | OR 1.28 [0.31, 5.37] | 1 study · 129 participants | Very low |
Higher vs lower degree of injury Clinical pregnancy per woman randomised: sensitivity analysis (including all studies) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | OR 1.31 [0.46, 3.73] | 1 study · 129 participants | Very low |
Endometrial injury vs control Live birth per woman randomised: sensitivity analysis (no high risk) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | OR 1.13 [0.63, 2.03] | 1 study · 229 participants | Low |
Endometrial injury vs control Live birth per woman randomised: sensitivity analysis (including all studies) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | no estimate extracted | 29 studies · 7792 participants | Very low |
Endometrial injury vs control Miscarriage per woman randomised (studies at low risk of selection bias and other bias) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | OR 0.88 [0.68, 1.13] | 8 studies · 4402 participants | Moderate |
Endometrial injury vs control Miscarriage per woman randomised: sensitivity analysis (no high risk) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | OR 1.17 [0.38, 3.58] | 1 study · 229 participants | Low |
Endometrial injury vs control Miscarriage per woman randomised: sensitivity analysis (including all studies) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | OR 1.03 [0.85, 1.25] | 30 studies · 8092 participants | Low |
Endometrial injury vs control Clinical pregnancy per woman randomised (studies at low risk of selection bias and other bias) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | OR 1.08 [0.95, 1.23] | 8 studies · 4402 participants | Moderate |
Endometrial injury vs control Clinical pregnancy per woman randomised: sensitivity analysis (no high‐risk) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | OR 1.16 [0.67, 2.02] | 1 study · 229 participants | Low |
Endometrial injury vs control Clinical pregnancy per woman randomised: sensitivity analysis (including all studies) · women undergoing assisted reproductive techniques Endometrial injury in women undergoing in vitro fertilisation (IVF) (2021) · Cochrane | no estimate extracted | 37 studies · 8786 participants | Very low |
Raloxifene vs placebo Relief of pelvic pain · women with endometriosis, following complete surgical excision of lesions Selective oestrogen receptor modulators (SERMs) for endometriosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Raloxifene vs placebo Adverse events ‐ pelvic pain · women with endometriosis, following complete surgical excision of lesions Selective oestrogen receptor modulators (SERMs) for endometriosis (2021) · Cochrane | RR 1.25 [0.63, 2.45] | 1 study · 93 participants | Very low |
Raloxifene vs placebo Adverse events ‐ ovarian cyst · women with endometriosis, following complete surgical excision of lesions Selective oestrogen receptor modulators (SERMs) for endometriosis (2021) · Cochrane | RR 1.57 [0.55, 4.43] | 1 study · 93 participants | Very low |
Raloxifene vs placebo Adverse events ‐ headache · women with endometriosis, following complete surgical excision of lesions Selective oestrogen receptor modulators (SERMs) for endometriosis (2021) · Cochrane | RR 1.06 [0.48, 2.37] | 1 study · 93 participants | Very low |
Raloxifene vs placebo Adverse events ‐ migraine · women with endometriosis, following complete surgical excision of lesions Selective oestrogen receptor modulators (SERMs) for endometriosis (2021) · Cochrane | RR 0.73 [0.28, 1.95] | 1 study · 93 participants | Very low |
Raloxifene vs placebo Adverse events ‐ depression · women with endometriosis, following complete surgical excision of lesions Selective oestrogen receptor modulators (SERMs) for endometriosis (2021) · Cochrane | RR 1.91 [0.62, 5.92] | 1 study · 93 participants | Very low |
Raloxifene vs placebo Biopsy‐proven recurrence of endometriosis · women with endometriosis, following complete surgical excision of lesions Selective oestrogen receptor modulators (SERMs) for endometriosis (2021) · Cochrane | RR 1.2 [0.66, 6.21] | 1 study · 93 participants | Very low |
Fresh vs frozen embryo transfer (cumulatively) Live birth rate: cumulatively · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 1.08 [0.95, 1.22] | 8 studies · 4712 participants | Moderate |
Fresh vs frozen embryo transfers Large for gestational age (birth weight above 90th percentile): after first ET · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 1.96 [1.51, 2.55] | 3 studies · 3940 participants | Low |
Fresh vs frozen embryo transfers Small for gestational age (birth weight below 10th percentile): cumulatively · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 0.36 [0.16, 0.8] | 1 study · 782 participants | Low |
Fresh vs frozen embryo transfers Small for gestational age (birth weight below 10th percentile): after first ET · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 0.82 [0.65, 1.05] | 3 studies · 3940 participants | Very low |
Fresh vs frozen embryo transfers Birth weight of babies born: singletons · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | no estimate extracted | 5 studies · 1607 participants | Moderate |
Fresh vs frozen embryo transfers Birth weight of babies born: multiples · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | no estimate extracted | 4 studies · 804 participants | Low |
Fresh vs frozen embryo transfer (cumulatively) OHSS: per cycle with ovarian hyperstimulation · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 0.26 [0.17, 0.39] | 6 studies · 4478 participants | Low |
Fresh vs frozen embryo transfer (cumulatively) Ongoing pregnancy rate: cumulatively · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 0.95 [0.75, 1.19] | 4 studies · 1245 participants | Moderate |
Fresh vs frozen embryo transfer (cumulatively) Miscarriage rate: cumulatively · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 1.06 [0.72, 1.55] | 2 studies · 986 participants | Very low |
Fresh vs frozen embryo transfer (cumulatively) Multiple pregnancy rate: cumulatively · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 0.88 [0.61, 1.25] | 2 studies · 986 participants | Very low |
Fresh vs frozen embryo transfer (cumulatively) Time to pregnancy · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | no estimate extracted | NR | No studies |
Fresh vs frozen embryo transfers Hypertensive disorders of pregnancy: cumulatively · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 0.7 [0.27, 1.82] | 1 study · 782 participants | Low |
Fresh vs frozen embryo transfers Hypertensive disorders of pregnancy: after first ET · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 2.15 [1.42, 3.25] | 3 studies · 3940 participants | Low |
Fresh vs frozen embryo transfers Large for gestational age (birth weight above 90th percentile): cumulatively · women undergoing assisted reproduction Fresh versus frozen embryo transfers in assisted reproduction (2021) · Cochrane | OR 1.97 [0.63, 6.15] | 1 study · 782 participants | Low |
Oxytocin antagonists vs control Live birth · women undergoing embryo transfer as part of assisted reproduction Oxytocin antagonists for assisted reproduction (2021) · Cochrane | RR 1.05 [0.88, 1.24] | 1 study · 800 participants | Low |